Name, professional designation (MD/PhD/other), institution/organization, professional role, email, work setting, field of research/specialty, disease state, gender, and ethnicity.

NIH Biosketch or equivalent (maximum 5 pages)

Please tell us why you are interested in this workshop in 500 words or less. Please include:

• A description of your proposed clinical trial protocol in cancer immunotherapy research and development
• Trial reagent availability support currently available
• A description of your career path up to this point and your aspirations for its future

Must provide a statement of support stating that the applicant will have time and relevant resources provided to conduct or oversee their trial (e.g. research nurse, appropriate equipment, etc). 

• A description of the proposed clinical trial
• Program support now available or intended for the term of the trial
• The candidate’s role and academic or other appointment(s)
• Plans and potential for the applicant to seek funding internally or externally

A one-page summary of your proposed interventional or observational study. Please include a one-page summary of the unmet clinical need you will be addressing, your immunologic goals, the biomarkers proposed, your hypotheses, and the proposed requisite number of patients and timeline.

Applicants must review and acknowledge a confidentiality statement. 

Established in 2022 in loving memory of Dr. Martin “Mac” Cheever, this fund recognizes his many contributions to the field of cancer immunotherapy by providing travel awards to deserving early career investigators pursuing excellence in clinical trial design.

To continue Dr. Cheever’s passion for improving immunotherapy protocols, each year, SITC will identify two individuals to receive a Martin “Mac” Cheever Excellence in Clinical Trial Design - Travel Award. One awardee will be selected from the participants in the SITC’s Clinical Immuno-Oncology Network (SCION) Workshop as having the most simple and elegant protocol at the close of the intensive and selective workshop. 

The second awardee will be selected from the participants in the SITC’s Clinical Immuno-Oncology Network (SCION) Workshop as having the best protocol focused on primary immunoprevention and immune interception. For this award, SITC will consider a trial with protocols which address immunotherapies to prevent primary cancer, including (but not limited to) methods to identify and stimulate immune recognition of precursor or preneoplastic lesions, strategies to provide prophylactic immunity against cancer, immunotherapies for precancerous conditions or immunoprevention of their recurrence in patients with high-risk familial cancers. Protocols for smaller pilot studies will also be considered.  

Both awardees will receive flight, hotel, and meal reimbursement to fully support their travel to the SITC Annual Meeting in the same year that they are selected as the recipients of the award.